KM Research Hub
← 返回论文库
已完成 入排:排除 图源:可得 入排置信度 0.96

Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD-mutated AML.

Mark J Levis, Mehdi Hamadani, Brent R Logan, Richard J Jones, Anurag K Singh, Mark R Litzow, John R Wingard, Esperanza B Papadopoulos, Alexander E Perl, Robert J Soiffer, Celalettin Ustun, Masumi Ueda Oshima, Geoffrey L Uy, Edmund K Waller, Sumithira Vasu, Melhem Solh, Asmita Mishra, Lori S Muffly, Hee-Je Kim, Matthias Stelljes, Yuho Najima, Masahiro Onozawa, Kirsty Thomson, Arnon Nagler, Andrew H Wei, Guido Marcucci, Caroline Chen, Nahla Hasabou, Matt Rosales, Jason Hill, Stanley C Gill, Rishita Nuthethi, Denise King, Adam Mendizabal, Steven M Devine, Mary M Horowitz, Yi-Bin Chen

Blood 145(19) 2138-2148

PMID39775763
PMCIDPMC12105721
DOI10.1182/blood.2024025154
发表日期2025-01-08
入排依据:属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
摘要

摘要

BMT CTN (Blood and Marrow Transplant Clinical Trials Network) 1506 ("MORPHO") was a randomized study of gilteritinib compared with placebo as maintenance therapy after hematopoietic cell transplantation (HCT) for patients with FLT3-ITD-mutated acute myeloid leukemia (AML). A key secondary end point was to determine the impact on survival of before and/or after HCT measurable residual disease (MRD), as determined using a highly sensitive assay for FLT3-ITD mutations. Generally, gilteritinib maintenance therapy was associated with improved relapse-free survival (RFS) for participants with detectable peri-HCT MRD, whereas no benefit was evident for those lacking detectable MRD. We conducted a post hoc analysis of the data and found that the level of MRD detected with this approach correlated remarkably with RFS and relapse risk, and that MRD detectable at any level negatively affected RFS. In the placebo arm, 42.2% of participants with detectable FLT3-ITD MRD relapsed compared with 13.4% of those without detectable MRD. We found that 14.8% of participants had multiple FLT3-ITD clones detected as MRD and had worse survival irrespective of treatment arm. Finally, we examined the kinetics of FLT3-ITD clonal relapse or eradication and found that participants on the placebo arm with detectable MRD relapsed rapidly after HCT, often within a few weeks. MRD-positive participants on the gilteritinib arm relapsed either with FLT3 wild-type clones (assessed by capillary electrophoresis), after cessation of gilteritinib with persistent MRD, or on progression of multiclonal disease. These data demonstrate the potential of FLT3-ITD MRD to guide therapy with gilteritinib for this subtype of AML. This trial was registered at www.clinicaltrials.gov as #NCT02997202.

KM 提取结果

1 个 Figure · 1 个 KM 面板

进入结果中心
KM Figure1 个面板

Figure 1

Increasing_levels_of_MRD_correlate_with_a_lower_probability_of_RFS_after_HCT_

RFS

Figure 1 · Panel Increasing_levels_of_MRD_correlate_with_a_lower_probability_of_RFS_after_HCT_

complete 待 EXE 对齐 预期 4 条 已提取 4 条

Panel Increasing_levels_of_MRD_correlate_with_a_lower_probability_of_RFS_after_HCT_ 是同一 Figure 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
其他 Figure(6,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1.RFS according to FLT3-ITD MRD detected before or after HCT. (A) RFS by randomization arm for all participants with FLT3-ITD MRD detected immediately before beginning pre-HCT conditioning. (B) RFS by randomization arm for all participants with FLT3-ITD MRD detected after engraftment was confirmed and before randomization to either gilteritinib or placebo. 95% CI, 95% confidence interval; HR, hazard ratio.
非 KM Figure
Figure 2.Relapse risk according to MRD level. RFS for participants with no detectable FLT3-ITD MRD is compared with RFS for participants with increasing levels of MRD. No MRD refers to no detectable MRD before or after HCT; MRD6 indicates mutant reads per total reads of ≥10 −6 but <10 −5 ; MRD5 indicates mutant reads per total reads of ≥10 −5 but <10 –4 ; and MRD4 indicates mutant reads per total reads of ≥10 −4 . (A) Placebo arm. (B) Gilteritinib arm. (C) Forest plot of cumulative incidence of relapse for gilteritinib vs placebo by level of MRD. 95% CI, 95% confidence interval; HR, hazard ratio; NE, not estimable.
非 KM Figure
Figure 3.Kinetics of clonal relapse and eradication in participants with post-HCT MRD. Each line on the plots depicts a single FLT3-ITD clone detected with the MRD assay, starting with randomization. In a limited number of cases, a sample was available at relapse, analyzed with conventional capillary electrophoresis PCR, and the length of the FLT3-ITD clone was identical to the clone detected in the MRD assay. These clones are depicted with red lines. The blue lines depict cases in which the relapse specimen was not available for analysis and so the length could not be confirmed. (A) Placebo arm, from randomization to 2 years of follow-up. (B) Placebo arm, depicting only the first 24 weeks of follow-up after randomization. (C) Gilteritinib arm, from randomization to 2 years of follow-up. (D) Gilteritinib arm, depicting only the first 24 weeks of follow-up after randomization.
非 KM Figure
Figure 4.Time course of clonal eradication by treatment arm. FLT3-ITD clones detected after HCT (ie, immediately after HCT, before randomization). Clonal eradication is defined as a previously detected FLT3-ITD clone becoming undetectable and not recurring again in a participant who was alive and disease free at completion of follow-up.
非 KM Figure
Figure 5.Case examples from gilteritinib arm. MRD, relapse, and drug exposures are displayed for 6 participants randomized to gilteritinib. Note that all investigators and participants were blinded to both study drug and MRD status. The colored thin lines represent the FLT3-ITD MRD clones and the thick black bars depict the periods when the participant was being treated with gilteritinib. Pt (participant) 1: 3 clones (21, 30, 45 base pairs [bp]) detected before and after HCT. Started gilteritinib on post-HCT day +41, maintained continuously on 120 mg/d for 24 months. The 30-bp clone was not detected at 2 time points, then rose steadily until 24 months after HCT. Gilteritinib was stopped per protocol, with the pt still in morphologic remission, and the pt relapsed 6 weeks later. Pt 2: single 30-bp clone detected before and after HCT. Started gilteritinib on post-HCT day 43. Clone eradicated, but pt relapsed 8 months after HCT with AML confirmed by PCR/capillary electrophoresis to be wild-type FLT3. Pt 3: single 54-bp clone detected both before and after HCT. Started gilteritinib on post-HCT day 35, with concomitant posaconazole. Lactate dehydrogenase was elevated to grade 3 and gilteritinib was decreased briefly to 80 mg/d, and then discontinued permanently on day +51. Relapsed on post-HCT day 134. Pt 4: single 42-bp clone detected before and after HCT. Started gilteritinib on post-HCT day 86, maintained continuously for 24 months, then stopped per protocol. The 42-bp clone was detected throughout, slowly decreasing in level. Pt alive and relapse free 49 months after HCT. Pt 5: 5 clones detected before HCT, all negative immediately after HCT. A new 159-bp clone appeared after HCT, before randomization. Started gilteritinib with concomitant itraconazole, but the gilteritinib had to be held twice for thrombocytopenia and resumed at 80 mg/d, with a resultant gilteritinib trough level of only 77.5 ng/mL (which is approximately one-third the median trough level for all other participants 17 ). The 159-bp clone became undetectable, but the 21-bp clone that had been detected before HCT reappeared on post-HCT day 142. Pt relapsed with the 21-bp and the 57-bp clone while on 80 mg/d gilteritinib. Pt 6: 2 clones detected before HCT, and a 63-bp clone persisted after HCT. Started gilteritinib on post-HCT day 50 and posaconazole started prophylactically on day post-HCT day 70. The absolute neutrophil count dropped to 100/mm 3 on post-HCT day 105 and gilteritinib was stopped. Gilteritinib was resumed on post-HCT day 131 (again with concomitant posaconazole), but the neutrophil count decreased again and the study drug was permanently stopped on post-HCT day 138. Pt relapsed 2 months later with the 63-bp clone.
非 KM Figure
Figure 6.Multiclonal FLT3-ITD mutations and RFS. (A) 54 participants were found to have multiple FLT3-ITD clones using the MRD assay peri-HCT. The Kaplan-Meier curve depicts RFS, irrespective of treatment arm, for these 54 participants compared with all other participants. (B) RFS for these same 54 participants compared with those with no MRD before and after HCT or those with only a single FLT3-ITD clone detected either before and after HCT. (C) RFS for participants on the placebo arm according to peri-HCT FLT3-ITD MRD status. The P value refers to the comparison between the “no MRD” and “single-clone MRD.” The P value comparing the single-clone and multiclonal MRD curves is .022 (not shown). (D) RFS for participants on the gilteritinib arm according to peri-HCT FLT3-ITD MRD status. The P value refers to the comparison between the “no MRD” and “multiclonal MRD.” The P value comparing “no MRD” and “single-clonal MRD” curves is .044 (not shown). HR, hazard ratio.
非 KM Figure